Becton, Dickinson and Company (NYSE:BDX) Stock Unloaded Rep. Lisa C. McClain

Representative Lisa C. McClain (R-Michigan) recently sold shares of Becton, Dickinson and Company (NYSE:BDX). In a filing disclosed on August 13th, the Representative disclosed that they had sold between $1,001 and $15,000 in Becton, Dickinson and Company stock on June 24th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Autoliv (NYSE:ALV) on 8/4/2025.
• Sold $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 8/4/2025.
• Sold $1,001 – $15,000 in shares of Applied Materials (NASDAQ:AMAT) on 8/4/2025.
• Sold $1,001 – $15,000 in shares of Arthur J. Gallagher & Co. (NYSE:AJG) on 8/4/2025.
• Sold $1,001 – $15,000 in shares of SAP (NYSE:SAP) on 7/22/2025.
• Purchased $1,001 – $15,000 in shares of XPO (NYSE:XPO) on 7/22/2025.
• Purchased $1,001 – $15,000 in shares of Lithia Motors (NYSE:LAD) on 7/22/2025.
• Sold $1,001 – $15,000 in shares of Sanofi (NASDAQ:SNY) on 7/22/2025.
• Sold $1,001 – $15,000 in shares of Waters (NYSE:WAT) on 7/22/2025.
• Purchased $1,001 – $15,000 in shares of Group 1 Automotive (NYSE:GPI) on 7/22/2025.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX opened at $195.22 on Tuesday. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a twelve month low of $163.33 and a twelve month high of $251.99. The stock’s 50 day moving average is $178.66 and its 200-day moving average is $196.21. The firm has a market capitalization of $55.96 billion, a price-to-earnings ratio of 35.11, a PEG ratio of 1.47 and a beta of 0.20.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping analysts’ consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. The company had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. During the same period in the prior year, the firm earned $3.50 earnings per share. Becton, Dickinson and Company’s revenue for the quarter was up 10.4% on a year-over-year basis. Sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio is presently 74.82%.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Northcape Wealth Management LLC grew its stake in Becton, Dickinson and Company by 0.5% in the 1st quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier’s stock valued at $2,248,000 after purchasing an additional 51 shares during the period. Alpha Omega Wealth Management LLC grew its stake in shares of Becton, Dickinson and Company by 5.7% during the 1st quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier’s stock worth $225,000 after acquiring an additional 53 shares during the period. Brady Family Wealth LLC grew its stake in shares of Becton, Dickinson and Company by 1.2% during the 1st quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier’s stock worth $989,000 after acquiring an additional 53 shares during the period. Diversified Trust Co grew its stake in shares of Becton, Dickinson and Company by 4.7% during the 1st quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier’s stock worth $272,000 after acquiring an additional 53 shares during the period. Finally, REAP Financial Group LLC grew its stake in shares of Becton, Dickinson and Company by 75.3% during the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 55 shares during the period. Institutional investors own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. This represents a 19.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David Shan sold 1,166 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total value of $199,607.54. Following the transaction, the executive vice president owned 4,575 shares of the company’s stock, valued at $783,194.25. The trade was a 20.31% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 3,214 shares of company stock worth $579,206. 0.36% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

BDX has been the topic of a number of research reports. Bank of America lowered Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $190.00 target price on the stock. in a research report on Thursday, May 1st. Barclays lowered their target price on Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating on the stock in a research report on Tuesday, June 3rd. Wells Fargo & Company increased their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. Wall Street Zen raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Finally, Raymond James Financial lowered Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research report on Friday, May 2nd. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $211.44.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.